Cargando…

Optimal duration of androgen deprivation therapy following radiation therapy in intermediate- or high-risk non-metastatic prostate cancer: A systematic review and meta-analysis

OBJECTIVES: To investigate current evidence on the optimal duration of adjuvant hormone deprivation for prostate cancer treated with radiation therapy with curative intent. MATERIALS AND METHODS: A systematic search was performed in electronic databases. Data from randomized trials comparing differe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Leal, Frederico, de Figueiredo, Maximiliano Augusto Novis, Sasse, Andre Deeke
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Sociedade Brasileira de Urologia 2015
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4752134/ https://www.ncbi.nlm.nih.gov/pubmed/26200535 http://dx.doi.org/10.1590/S1677-5538.IBJU.2014.0412

Ejemplares similares

Effects of statin use on the response duration to androgen deprivation therapy in metastatic prostate cancer
por: Jung, Jaeyoon, et al.
Publicado: (2015)

Cost-effectiveness of cetuximab and panitumumab for chemotherapy-refractory metastatic colorectal cancer
por: Carvalho, Adriana Camargo, et al.
Publicado: (2017)

Duration of androgen deprivation therapy with maximum androgen blockade for localized prostate cancer
por: Fujimoto, Naohiro, et al.
Publicado: (2011)

Radiotherapy with or without androgen deprivation therapy in intermediate risk prostate cancer?
por: Amit, Uri, et al.
Publicado: (2019)

Trends in Androgen Deprivation Use in Men With Intermediate-Risk Prostate Cancer Who Underwent Radiation Therapy
por: Agrawal, Vishesh, et al.
Publicado: (2022)

Adjuvant androgen deprivation therapy for prostate cancer treated with radiation therapy
por: Siddiqui, Zaid A., et al.
Publicado: (2018)

Patients’ Preferences for Androgen Deprivation Therapy in the Treatment of Intermediate-Risk Prostate Cancer
por: De, Brian, et al.
Publicado: (2022)

A Phase 1 study Combining Pexidartinib, Radiation Therapy, and Androgen Deprivation Therapy in Men With Intermediate- and High-Risk Prostate Cancer
por: Hamid, Muhammad, et al.
Publicado: (2021)

Efficacy and Prognostic Factors of Androgen Deprivation Therapy Combined with Radiation Therapy for Prostate Cancer
por: Zeng, Siping, et al.
Publicado: (2021)

The role of androgen deprivation therapy on biochemical failure and distant metastasis in intermediate-risk prostate cancer: effects of radiation dose escalation
por: Ludwig, Michelle S, et al.
Publicado: (2015)

Clinical effect of abiraterone acetate in Korean patients with metastatic castration-resistant prostate cancer according to duration of androgen deprivation therapy
por: Kim, Ki Bom, et al.
Publicado: (2015)

Immune Modulation by Androgen Deprivation and Radiation Therapy: Implications for Prostate Cancer Immunotherapy
por: Kalina, Jennifer L., et al.
Publicado: (2017)

Prostate cancer, insulin, and androgen deprivation therapy
por: Stattin, P, et al.
Publicado: (2003)

Association between duration and type of androgen deprivation therapy and risk of diabetes in men with prostate cancer
por: Crawley, Danielle, et al.
Publicado: (2016)

Intermediate-risk prostate cancer patients treated with androgen deprivation therapy and a hypofractionated radiation regimen with or without image guided radiotherapy
por: Valeriani, Maurizio, et al.
Publicado: (2013)

Is there still a role for bilateral orchidectomy in androgen-deprivation therapy for metastatic prostate cancer?
por: Atta, Mohamed Adel, et al.
Publicado: (2019)

What Is Your Choice for Androgen Deprivation Therapy in Metastatic Prostate Carcinoma: Surgical or Medical?
por: Salih Semiz, Huseyin, et al.
Publicado: (2022)

Reversing the effects of androgen-deprivation therapy in men with metastatic castration-resistant prostate cancer
por: Marshall, Catherine H., et al.
Publicado: (2021)

Androgen deprivation therapy as backbone therapy in the management of prostate cancer
por: Merseburger, Axel S, et al.
Publicado: (2016)

Androgen deprivation therapy and radiotherapy in intermediate-risk prostate cancer: A systematic review and meta-analysis
por: Chen, Jiuzhou, et al.
Publicado: (2023)

Impact of androgen deprivation therapy on mortality of prostate cancer patients with COVID-19: a propensity score-based analysis
por: Duarte, Mateus Bringel Oliveira, et al.
Publicado: (2021)

Relationship between prostate volume changes and treatment duration of neoadjuvant androgen deprivation during intensity-modulated radiation therapy for Japanese patients with prostate cancer
por: Tomida, Masashi, et al.
Publicado: (2016)

Effects of androgen deprivation therapy duration and Gleason grade on survival outcomes of high risk prostate cancer
por: Kim, Do Kyung, et al.
Publicado: (2019)

Heterogeneity in high-risk prostate cancer treated with high-dose radiation therapy and androgen deprivation therapy
por: Cagney, Daniel N., et al.
Publicado: (2017)

Long-term outcomes of dose-escalated intensity modulated radiation therapy alone without androgen deprivation therapy for patients with intermediate and high-risk prostate cancer
por: Gadia, Rafael, et al.
Publicado: (2016)

Reply: Prostate cancer, insulin and androgen deprivation therapy
por: Lehrer, S
Publicado: (2003)

Androgen deprivation therapy for prostate cancer and risk of dementia
por: Robinson, David, et al.
Publicado: (2019)

Androgen deprivation therapy in high risk prostate cancer
por: Van Dams, Ritchell, et al.
Publicado: (2019)

Cardiovascular Risks of Androgen Deprivation Therapy for Prostate Cancer
por: Corona, Giovanni, et al.
Publicado: (2021)

First Line Androgen Deprivation Therapy Duration Is Associated with the Efficacy of Abiraterone Acetate Treated Metastatic Castration-Resistant Prostate Cancer after Docetaxel
por: Li, Jian-Ri, et al.
Publicado: (2017)

Androgen Deprivation Therapy Toxicity and Management for Men Receiving Radiation Therapy
por: Johnson, Matthew E., et al.
Publicado: (2012)

WHO SHOULD RECEIVE NOVEL HORMONAL THERAPY WITH ANDROGEN DEPRIVATION THERAPY IN METASTATIC HORMONE SENSITIVE PROSTATE CANCER?
por: Omrčen, Tomislav
Publicado: (2019)

International survey of androgen deprivation therapy (ADT) for non-metastatic prostate cancer in 19 countries
por: Liede, Alexander, et al.
Publicado: (2016)

Influence of Baseline Cardiovascular Comorbidities on Mortality after Androgen Deprivation Therapy for Metastatic Prostate Cancer
por: Wu, Szu-Yuan, et al.
Publicado: (2020)

Differential Impact of TGFB1 Variation by Metastatic Status in Androgen-Deprivation Therapy for Prostate Cancer
por: Shiota, Masaki, et al.
Publicado: (2021)

Treatment intensification for metastatic prostate cancer: New treatment landscapes in androgen deprivation‐based therapy
por: Turco, Fabio, et al.
Publicado: (2022)

An Update on the Changing Indications for Androgen Deprivation Therapy for Prostate Cancer
por: Myklak, Kristene, et al.
Publicado: (2011)

Metabolomic effects of androgen deprivation therapy treatment for prostate cancer
por: Chi, Jen‐Tsan, et al.
Publicado: (2020)

Androgen deprivation therapy for prostate cancer and the risk of hematologic disorders
por: Liu, Jui-Ming, et al.
Publicado: (2020)

Relugolix – The novel oral androgen deprivation therapy for prostate cancer
por: Jena, Rahul
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_5ft6bdaior27sim64que4fjbo1